Casdin Capital
Latest statistics and disclosures from Casdin Capital's latest quarterly 13F-HR filing:
- Top 5 stock holdings are WGS, RVMD, BLFS, LAB, RLAY, and represent 59.88% of Casdin Capital's stock portfolio.
- Added to shares of these 10 stocks: GH (+$29M), TXG (+$23M), DNLI (+$16M), LAB (+$14M), RLAY (+$14M), DXCM (+$12M), SRRK (+$12M), CI (+$11M), ILMN (+$9.8M), DGX (+$8.7M).
- Started 7 new stock positions in DXCM, SRRK, LEGN, CI, TSHA, DGX, TXG.
- Reduced shares in these 5 stocks: RNA (-$56M), GPCR (-$26M), BLFS (-$18M), RVMD (-$5.6M), .
- Sold out of its position in EXAS.
- Casdin Capital was a net buyer of stock by $78M.
- Casdin Capital has $1.6B in assets under management (AUM), dropping by 34.24%.
- Central Index Key (CIK): 0001534261
Tip: Access up to 7 years of quarterly data
Positions held by Casdin Capital consolidated in one spreadsheet with up to 7 years of data
Download as csvPortfolio Holdings for Casdin Capital
Casdin Capital holds 38 positions in its portfolio as reported in the December 2025 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Genedx Holdings Corp Com Cl A (WGS) | 24.3 | $391M | 3.0M | 130.06 |
|
|
| Revolution Medicines (RVMD) | 12.8 | $205M | -2% | 2.6M | 79.65 |
|
| Biolife Solutions Com New (BLFS) | 8.9 | $144M | -11% | 6.0M | 24.18 |
|
| D Fluidigm Corp Del (LAB) | 7.1 | $114M | +14% | 89M | 1.28 |
|
| Relay Therapeutics (RLAY) | 6.8 | $110M | +14% | 13M | 8.46 |
|
| Structure Therapeutics Sponsored Ads (GPCR) | 5.1 | $82M | -24% | 1.2M | 69.55 |
|
| Illumina (ILMN) | 4.9 | $79M | +14% | 600k | 131.16 |
|
| Avidity Biosciences Ord (RNA) | 4.5 | $72M | -43% | 1.0M | 72.13 |
|
| Beam Therapeutics (BEAM) | 2.8 | $44M | 1.6M | 27.72 |
|
|
| Guardant Health (GH) | 2.4 | $39M | +280% | 380k | 102.14 |
|
| Maze Therapeatics (MAZE) | 2.0 | $31M | 759k | 41.43 |
|
|
| Denali Therapeutics (DNLI) | 1.9 | $30M | +106% | 1.8M | 16.51 |
|
| Alnylam Pharmaceuticals (ALNY) | 1.9 | $30M | +36% | 75k | 397.65 |
|
| Neurogene (NGNE) | 1.7 | $27M | 1.3M | 20.60 |
|
|
| 10x Genomics Cl A Com (TXG) | 1.4 | $23M | NEW | 1.4M | 16.31 |
|
| Silverback Therapeutics (SPRY) | 1.2 | $19M | 1.6M | 11.65 |
|
|
| Tempus Ai Cl A (TEM) | 1.1 | $17M | 294k | 59.05 |
|
|
| UnitedHealth (UNH) | 1.0 | $17M | +100% | 50k | 330.11 |
|
| Septerna (SEPN) | 1.0 | $15M | 553k | 27.88 |
|
|
| Hims & Hers Health Com Cl A (HIMS) | 0.8 | $13M | +67% | 385k | 32.47 |
|
| Veracyte (VCYT) | 0.7 | $12M | 276k | 42.10 |
|
|
| Dex (DXCM) | 0.7 | $12M | NEW | 175k | 66.37 |
|
| Scholar Rock Hldg Corp (SRRK) | 0.7 | $12M | NEW | 260k | 44.05 |
|
| Cigna Corp (CI) | 0.7 | $11M | NEW | 40k | 275.23 |
|
| Prime Medicine (PRME) | 0.7 | $11M | 3.2M | 3.47 |
|
|
| Incyte Corporation (INCY) | 0.6 | $9.9M | 100k | 98.77 |
|
|
| Quest Diagnostics Incorporated (DGX) | 0.5 | $8.7M | NEW | 50k | 173.53 |
|
| Taysha Gene Therapies Com Shs (TSHA) | 0.5 | $8.3M | NEW | 1.5M | 5.50 |
|
| Pacific Biosciences of California (PACB) | 0.5 | $7.9M | +483% | 4.2M | 1.87 |
|
| Legend Biotech Corp Sponsored Ads (LEGN) | 0.3 | $4.7M | NEW | 215k | 21.74 |
|
| Bridgebio Oncology Therapeut Com New (BBOT) | 0.2 | $3.5M | 282k | 12.52 |
|
|
| Absci Corp (ABSI) | 0.2 | $3.4M | 973k | 3.49 |
|
|
| Contineum Therapeutics Cl A (CTNM) | 0.1 | $1.7M | 148k | 11.43 |
|
|
| Monte Rosa Therapeutics (GLUE) | 0.1 | $1.3M | 86k | 15.68 |
|
|
| Century Therapeutics (IPSC) | 0.1 | $1.2M | 1.2M | 0.99 |
|
|
| Recursion Pharmaceuticals In Cl A (RXRX) | 0.0 | $676k | 165k | 4.09 |
|
|
| Ginkgo Bioworks Holdings Cl A New (DNA) | 0.0 | $303k | 37k | 8.31 |
|
|
| Tenaya Therapeutics (TNYA) | 0.0 | $258k | 362k | 0.71 |
|
Past Filings by Casdin Capital
SEC 13F filings are viewable for Casdin Capital going back to 2015
- Casdin Capital 2025 Q4 filed Feb. 17, 2026
- Casdin Capital 2025 Q3 filed Nov. 14, 2025
- Casdin Capital 2025 Q2 filed Aug. 14, 2025
- Casdin Capital 2025 Q1 filed May 15, 2025
- Casdin Capital 2024 Q4 filed Feb. 14, 2025
- Casdin Capital 2024 Q3 filed Nov. 14, 2024
- Casdin Capital 2024 Q2 restated filed Oct. 18, 2024
- Casdin Capital 2024 Q2 filed Aug. 14, 2024
- Casdin Capital 2024 Q1 filed May 15, 2024
- Casdin Capital 2023 Q4 filed Feb. 14, 2024
- Casdin Capital 2023 Q3 filed Nov. 14, 2023
- Casdin Capital 2023 Q2 filed Aug. 14, 2023
- Casdin Capital 2023 Q1 filed May 15, 2023
- Casdin Capital 2022 Q4 filed Feb. 14, 2023
- Casdin Capital 2022 Q3 filed Nov. 14, 2022
- Casdin Capital 2022 Q2 filed Aug. 15, 2022